| ECCO guidelines on therapeutics in Crohn's disease: medical treatment J Torres, S Bonovas, G Doherty, T Kucharzik, JP Gisbert, T Raine, ... Journal of Crohn's and Colitis 14 (1), 4-22, 2020 | 1063 | 2020 |
| European evidence based consensus for endoscopy in inflammatory bowel disease V Annese, M Daperno, MD Rutter, A Amiot, P Bossuyt, J East, M Ferrante, ... Journal of Crohn's and Colitis 7 (12), 982-1018, 2013 | 916 | 2013 |
| Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial JF Colombel, R Panaccione, P Bossuyt, M Lukas, F Baert, T Vaňásek, ... The Lancet 390 (10114), 2779-2789, 2017 | 822 | 2017 |
| ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment M Adamina, S Bonovas, T Raine, A Spinelli, J Warusavitarne, A Armuzzi, ... Journal of Crohn's and Colitis 14 (2), 155-168, 2020 | 451 | 2020 |
| Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after ileocolonic resection M Regueiro, BG Feagan, B Zou, J Johanns, MA Blank, M Chevrier, ... Gastroenterology 150 (7), 1568-1578, 2016 | 318 | 2016 |
| Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients … G D’Haens, S Vermeire, G Lambrecht, F Baert, P Bossuyt, B Pariente, ... Gastroenterology 154 (5), 1343-1351. e1, 2018 | 303 | 2018 |
| Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials G d'Haens, R Panaccione, F Baert, P Bossuyt, JF Colombel, S Danese, ... The Lancet 399 (10340), 2015-2030, 2022 | 178 | 2022 |
| Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease D Labaere, A Smismans, A Van Olmen, P Christiaens, G D’Haens, ... United European Gastroenterology Journal 2 (1), 30-37, 2014 | 172 | 2014 |
| Deep remission at 1 year prevents progression of early Crohn’s disease RC Ungaro, C Yzet, P Bossuyt, FJ Baert, T Vanasek, GR D’Haens, ... Gastroenterology 159 (1), 139-147, 2020 | 159 | 2020 |
| Increasing incidence of Clostridium difficile -associated diarrhea in inflammatory bowel disease P Bossuyt, J Verhaegen, G Van Assche, P Rutgeerts, S Vermeire Journal of Crohn's and Colitis 3 (1), 4-7, 2009 | 155 | 2009 |
| Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection S Ben-Horin, M Margalit, P Bossuyt, J Maul, Y Shapira, D Bojic, ... Clinical Gastroenterology and Hepatology 7 (9), 981-987, 2009 | 153 | 2009 |
| Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn’s disease D Drobne, P Bossuyt, C Breynaert, T Cattaert, NV Casteele, ... Clinical Gastroenterology and Hepatology 13 (3), 514-521. e4, 2015 | 149 | 2015 |
| Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal … M Ferrante, R Panaccione, F Baert, P Bossuyt, JF Colombel, S Danese, ... The Lancet 399 (10340), 2031-2046, 2022 | 148 | 2022 |
| Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study A Moens, CJ van der Woude, M Julsgaard, E Humblet, J Sheridan, ... Alimentary pharmacology & therapeutics 51 (1), 129-138, 2020 | 110 | 2020 |
| Vedolizumab induces endoscopic and histologic remission in patients with Crohn’s disease M Löwenberg, S Vermeire, N Mostafavi, F Hoentjen, D Franchimont, ... Gastroenterology 157 (4), 997-1006. e6, 2019 | 108 | 2019 |
| Long-term clinical effectiveness of ustekinumab in patients with Crohn’s disease who failed biologic therapies: a national cohort study C Liefferinckx, B Verstockt, A Gils, M Noman, C Van Kemseke, E Macken, ... Journal of Crohn's and Colitis 13 (11), 1401-1409, 2019 | 103 | 2019 |
| Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection S Ben-Horin, M Margalit, P Bossuyt, J Maul, Y Shapira, D Bojic, ... Journal of Crohn's and Colitis 4 (2), 194-198, 2010 | 98 | 2010 |
| Development of the IBD disk: a visual self-administered tool for assessing disability in inflammatory bowel diseases S Ghosh, E Louis, L Beaugerie, P Bossuyt, G Bouguen, A Bourreille, ... Inflammatory bowel diseases 23 (3), 333-340, 2017 | 95 | 2017 |
| Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density P Bossuyt, H Nakase, S Vermeire, G De Hertogh, T Eelbode, M Ferrante, ... Gut 69 (10), 1778-1786, 2020 | 92 | 2020 |
| European Crohn’s and Colitis Organisation V Annese, M Daperno, MD Rutter, A Amiot, P Bossuyt, J East, M Ferrante, ... European evidence based consensus for endoscopy in inflammatory bowel …, 2013 | 89 | 2013 |
